Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Immunoglobulin heavy variable 3-52 (IGHV3-52) gene encodes a variable region of the immunoglobulin heavy chain and is part of the immunoglobulin superfamily (IgSF)[1]. This variable region contributes to the antigen-binding domain of antibodies, pairing with light chain variable domains to form the antigen specificity site[1]. IGHV genes, including IGHV3-52, undergo somatic recombination and somatic hypermutation to generate antibody diversity essential for adaptive immune responses[1][2][4]. IGHV3-52 itself is not a drug target or receptor but comprises the genetic blueprint used by B lymphocytes to generate distinct antibodies by recombining with other V, D, and J segments[1][2]. The IGHV3 subclass, to which IGHV3-52 belongs, is known for its polymorphism and impact on antibody repertoire diversity across individuals[2][4]. Dysfunction or polymorphisms in variable segment genes can contribute to altered immunity, but IGHV3-52 is not established as a direct therapeutic target for drugs[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-52 (IGHV3-52).